Contact
searchSearch
HMP Global

First Report Managed Care

News

News
CNS-Active Polypharmacy Affects 10 Percent of Medicare MTM Enrollees in the US
03/06/2026
Hannah Musick
In a nationally representative Medicare Medication Therapy Management (MTM) cohort, 10.7% of enrollees experienced central nervous system (CNS)-active polypharmacy, yet only about one-third completed a comprehensive medication review,...
In a nationally representative Medicare Medication Therapy Management (MTM) cohort, 10.7% of enrollees experienced central nervous system (CNS)-active polypharmacy, yet only about one-third completed a comprehensive medication review,...
In a nationally representative...
03/06/2026
First Report Managed Care
News
GLOBIN Study Reports Promising First-Line Outcomes in Follicular Lymphoma
03/06/2026
Grace Taylor, MS, MA
First-line glofitamab plus obinutuzumab (GLOBIN) achieved a 100% response rate with manageable toxicity in patients with high-tumor burden follicular lymphoma, according to a phase II multicenter trial presented at the ASH Annual Meeting and...
First-line glofitamab plus obinutuzumab (GLOBIN) achieved a 100% response rate with manageable toxicity in patients with high-tumor burden follicular lymphoma, according to a phase II multicenter trial presented at the ASH Annual Meeting and...
First-line glofitamab plus...
03/06/2026
First Report Managed Care
News
Arthritis Activity Limitations Affect Nearly Half of US Adults
03/06/2026
Grace Taylor, MS, MA
Nearly half of US adults with arthritis reported activity limitations in 2023, underscoring persistent functional burden and missed national targets to reduce disability.
Nearly half of US adults with arthritis reported activity limitations in 2023, underscoring persistent functional burden and missed national targets to reduce disability.
Nearly half of US adults with...
03/06/2026
First Report Managed Care
News
Outpatient Management of Grade 1 CRS Safe in R/R Follicular Lymphoma
03/05/2026
Hannah Musick
In a multicenter US cohort of patients with relapsed or refractory (R/R) follicular lymphoma, grade 1 cytokine release syndrome (CRS) following bispecific antibody therapy was safely managed in the outpatient setting without compromising...
In a multicenter US cohort of patients with relapsed or refractory (R/R) follicular lymphoma, grade 1 cytokine release syndrome (CRS) following bispecific antibody therapy was safely managed in the outpatient setting without compromising...
In a multicenter US cohort of...
03/05/2026
First Report Managed Care
News
Enhancing Prediction of Long-Term Survival After CAR T in DLBCL
03/05/2026
Hannah Musick
In a single-center US cohort of patients with diffuse large B-cell lymphoma (DLBCL), achieving event-free survival at 12 months after CAR T therapy was associated with durable remission and a 68% 5-year progression-free survival rate.
In a single-center US cohort of patients with diffuse large B-cell lymphoma (DLBCL), achieving event-free survival at 12 months after CAR T therapy was associated with durable remission and a 68% 5-year progression-free survival rate.
In a single-center US cohort of...
03/05/2026
First Report Managed Care
News
NHANES Data Highlight Growing Severe Obesity Burden in US Adults
03/05/2026
Grace Taylor, MS, MA
New National Health and Nutrition Examination Survey (NHANES) data show that more than 40% of U.S. adults have obesity, with severe obesity continuing to rise and persistent disparities across age, sex, and racial groups.
New National Health and Nutrition Examination Survey (NHANES) data show that more than 40% of U.S. adults have obesity, with severe obesity continuing to rise and persistent disparities across age, sex, and racial groups.
New National Health and...
03/05/2026
First Report Managed Care
News
AI Roadmap Aims to Accelerate Nephrology Clinical Integration in US Care
03/04/2026
Hannah Musick
A state-of-the-art review outlines how artificial intelligence (AI) could enhance prediction, personalization, and workflow efficiency across acute kidney injury, chronic kidney disease, dialysis, and transplantation, while emphasizing the...
A state-of-the-art review outlines how artificial intelligence (AI) could enhance prediction, personalization, and workflow efficiency across acute kidney injury, chronic kidney disease, dialysis, and transplantation, while emphasizing the...
A state-of-the-art review...
03/04/2026
First Report Managed Care
News
Rising GLP-1 Adoption May Drive Significant Payer and Patient Cost Increases
03/04/2026
Hannah Musick
In a nationally representative US sample, adults with diabetes who used GLP-1 receptor agonists had significantly higher total, payer, and out-of-pocket health care expenditures than nonusers, even after adjustment for clinical and...
In a nationally representative US sample, adults with diabetes who used GLP-1 receptor agonists had significantly higher total, payer, and out-of-pocket health care expenditures than nonusers, even after adjustment for clinical and...
In a nationally representative...
03/04/2026
First Report Managed Care
News
CMS Extends GENEROUS Model Drug Pricing Deadline to April 2026
03/03/2026
Grace Taylor, MS, MA
The Centers for Medicare & Medicaid Services (CMS) has extended the extended the Generating Cost Reductions for U.S. Medicaid (GENEROUS) Model application deadline to April 30, 2026, giving drug manufacturers more time to participate in the...
The Centers for Medicare & Medicaid Services (CMS) has extended the extended the Generating Cost Reductions for U.S. Medicaid (GENEROUS) Model application deadline to April 30, 2026, giving drug manufacturers more time to participate in the...
The Centers for Medicare &...
03/03/2026
First Report Managed Care
Behind the Bill
Minnesota Sues HHS Over $243 Million Medicaid Funding Withholding: Federal Oversight and Program Integrity Dispute
03/03/2026
Danielle Sposato
The Minnesota Attorney General has filed a federal lawsuit challenging the US Department of Health and Human Services’ (HHS) decision to withhold approximately $243 million in federal Medicaid funding, initiating litigation over a dispute...
The Minnesota Attorney General has filed a federal lawsuit challenging the US Department of Health and Human Services’ (HHS) decision to withhold approximately $243 million in federal Medicaid funding, initiating litigation over a dispute...
The Minnesota Attorney General...
03/03/2026
First Report Managed Care

KOL Insights

Real-World Data, Artificial Intelligence, Health Care
Commentary
Powering Actionable Insights With Real-Time RWD Dashboards
02/11/2026
Sujay Jadhav
Health care generates massive amounts of real-world data (RWD), and that volume is only continuing to expand. By 2030, the global big data analytics market is expected to reach nearly $350 billion, with health care driving much of that...
Health care generates massive amounts of real-world data (RWD), and that volume is only continuing to expand. By 2030, the global big data analytics market is expected to reach nearly $350 billion, with health care driving much of that...
Health care generates massive...
02/11/2026
First Report Managed Care
NSCLC, Oncology Coverage, Oncology Access
Videos
What PALOMA-3 Signals for Coverage, Access, and Care Delivery in NSCLC
02/02/2026
Narjust Florez, MD
In this interview, Narjust Florez, MD, discusses how subcutaneous amivantamab from the PALOMA-3 study may improve patient experience, clinic workflow, and treatment adherence while highlighting ongoing unmet needs and real-world...
In this interview, Narjust Florez, MD, discusses how subcutaneous amivantamab from the PALOMA-3 study may improve patient experience, clinic workflow, and treatment adherence while highlighting ongoing unmet needs and real-world...
In this interview, Narjust...
02/02/2026
First Report Managed Care
Non-Small Cell Lung Cancer
Videos
Optimizing NSCLC Care Through Extended Dosing and Alternative Formulations
01/27/2026
Corrine Stahura, PharmD, BCOP
Corrine Stahura, PharmD, BCOP, discusses how extended dosing intervals and subcutaneous formulations in non–small cell lung cancer are improving patient convenience, reducing infusion center burden, and enhancing operational efficiency while...
Corrine Stahura, PharmD, BCOP, discusses how extended dosing intervals and subcutaneous formulations in non–small cell lung cancer are improving patient convenience, reducing infusion center burden, and enhancing operational efficiency while...
Corrine Stahura, PharmD, BCOP,...
01/27/2026
First Report Managed Care
Non-Small Cell Lung Cancer
Videos
Treatment Paradigms in NSCLC: Chemo-Based vs Non-Chemo Regimens
01/27/2026
Rajat Thawani, MD
Dr Rajat Thawani discusses how biomarker-driven strategies, emerging immunotherapies, and novel delivery approaches are rapidly redefining first-line non-small cell lung cancer (NSCLC) treatment—shifting care beyond traditional chemotherapy...
Dr Rajat Thawani discusses how biomarker-driven strategies, emerging immunotherapies, and novel delivery approaches are rapidly redefining first-line non-small cell lung cancer (NSCLC) treatment—shifting care beyond traditional chemotherapy...
Dr Rajat Thawani discusses how...
01/27/2026
First Report Managed Care
Non-Small Cell Lung Cancer
Videos
Evaluating Total Cost Considerations in Non–Small Cell Lung Cancer Care
01/27/2026
Estelamari Rodriguez, MD, MPH
As new subcutaneous and targeted therapies enter the NSCLC landscape, the true cost of care extends far beyond drug price alone. In this interview, Estelamari Rodriguez, MD, MPH, a thoracic oncologist at Sylvester Comprehensive Cancer Center,...
As new subcutaneous and targeted therapies enter the NSCLC landscape, the true cost of care extends far beyond drug price alone. In this interview, Estelamari Rodriguez, MD, MPH, a thoracic oncologist at Sylvester Comprehensive Cancer Center,...
As new subcutaneous and targeted...
01/27/2026
First Report Managed Care
Yuri Fesko, MD, PAMA, Health Care Policy, Medicare
Interview
PAMA and the Downstream Impact of Lab Reimbursement on Cancer Care Access
01/22/2026
Yuri Fesko, MD
In this interview, senior vice president and chief medical officer at Quest Diagnostics, Yuri Fesko, MD, discusses how Medicare laboratory reimbursement under PAMA threatens access to precision cancer diagnostics—particularly for rural and...
In this interview, senior vice president and chief medical officer at Quest Diagnostics, Yuri Fesko, MD, discusses how Medicare laboratory reimbursement under PAMA threatens access to precision cancer diagnostics—particularly for rural and...
In this interview, senior vice...
01/22/2026
First Report Managed Care
Long-Term Care, Post-Acute Care, Lobbying, Politics
Commentary
All Politics Is Local—Why Long-Term and Post-Acute Care Leaders Should Participate in Grassroots Advocacy
01/20/2026
Bill Charnetski
Local long-term and post-acute care leaders can’t afford to sit out politics—by embracing grassroots advocacy, sharing their expertise, and building relationships with lawmakers, they can directly shape the policies that affect their...
Local long-term and post-acute care leaders can’t afford to sit out politics—by embracing grassroots advocacy, sharing their expertise, and building relationships with lawmakers, they can directly shape the policies that affect their...
Local long-term and post-acute...
01/20/2026
Annals of Long-Term Care
Rural Hospitals, Behavioral Health, Coverage Gaps
Interview
Rural Hospitals on the Front Lines of Behavioral Health Coverage Gaps
01/15/2026
Shannon Werb
Shannon Werb, CEO of Array Behavioral Care, explains how uncertainty around Affordable Care Act (ACA) subsidies and Medicaid eligibility threatens to disrupt behavioral health care first—fueling treatment gaps, increased emergency department...
Shannon Werb, CEO of Array Behavioral Care, explains how uncertainty around Affordable Care Act (ACA) subsidies and Medicaid eligibility threatens to disrupt behavioral health care first—fueling treatment gaps, increased emergency department...
Shannon Werb, CEO of Array...
01/15/2026
First Report Managed Care
Rutzler Headshot
Commentary
Clean-up Your Defenses: Why Health Plans Can't Afford to Wait on Fraud Hygiene
12/08/2025
Erin Rutzler
Health plans must urgently shift from reactive, manual fraud efforts to proactive, technology-driven prepay strategies—supported by unified teams and expert talent—to combat increasingly fast, sophisticated fraud, waste, and abuse schemes and...
Health plans must urgently shift from reactive, manual fraud efforts to proactive, technology-driven prepay strategies—supported by unified teams and expert talent—to combat increasingly fast, sophisticated fraud, waste, and abuse schemes and...
Health plans must urgently shift...
12/08/2025
First Report Managed Care
Regulatory Insights
Subsidies, Savings, and Stalemates: What Congress's Year-End Gridlock Means for Health Plans in 2026
12/05/2025
Adam Colborn, JD
As health policy debates resurface in Washington, unresolved battles over ACA subsidies, health savings accounts, and PBM reform are shaping a high-stakes landscape for payers heading into the new year.
As health policy debates resurface in Washington, unresolved battles over ACA subsidies, health savings accounts, and PBM reform are shaping a high-stakes landscape for payers heading into the new year.
As health policy debates...
12/05/2025
First Report Managed Care

Issue Features

Sponsored
Explore the Clinical Data for JOURNAVX® (suzetrigine)
10/16/2025
JOURNAVX is an oral nonopioid indicated for the treatment of moderate-to-severe acute pain in adults—the first and only oral pain signal inhibitor highly selective for NaV1.81
JOURNAVX is an oral nonopioid indicated for the treatment of moderate-to-severe acute pain in adults—the first and only oral pain signal inhibitor highly selective for NaV1.81
JOURNAVX is an oral nonopioid...
10/16/2025
First Report Managed Care
Infographic
Nerandomilast in Patients With Idiopathic Pulmonary Fibrosis
08/06/2025
The infographic summarizes the FIBRONEER-IPF Phase 3 trial results, demonstrating nerandomilast significantly reduced the decline in forced vital capacity (FVC) over 52 weeks compared to placebo. Nerandomilast exhibited a favorable safety...
The infographic summarizes the FIBRONEER-IPF Phase 3 trial results, demonstrating nerandomilast significantly reduced the decline in forced vital capacity (FVC) over 52 weeks compared to placebo. Nerandomilast exhibited a favorable safety...
The infographic summarizes the...
08/06/2025
First Report Managed Care
Feature Story
More Specialists Should Gravitate Toward Episode-Based Care Models
05/12/2025
Lynn Carroll; Rahul Sharma
Health care organizations will be under increasing financial pressure in 2025 and beyond as they struggle to reduce costs while improving care quality—particularly as actions at the federal level threaten to severely disrupt the industry. Not...
Health care organizations will be under increasing financial pressure in 2025 and beyond as they struggle to reduce costs while improving care quality—particularly as actions at the federal level threaten to severely disrupt the industry. Not...
Health care organizations will...
05/12/2025
First Report Managed Care
Feature Story
Winning With Value-Based Care: Balancing Risk, Analytics, and Digital Innovation
05/12/2025
David J. Sand, MD, MBA; Lynn Carroll
Value-based care (VBC) is the future of health care. It is the best approach to improving patient outcomes, reducing costs and addressing overall population health through a focus on prevention, care coordination and overall wellness.
Value-based care (VBC) is the future of health care. It is the best approach to improving patient outcomes, reducing costs and addressing overall population health through a focus on prevention, care coordination and overall wellness.
Value-based care (VBC) is the...
05/12/2025
First Report Managed Care
Sponsored
The Teva Biosimilars Trend Report, Second Edition: Perspectives from Managed Care, Providers & Employers
03/27/2025
On behalf of Teva Pharmaceuticals, we are pleased to present the second edition of The Teva Biosimilars Trend Report. This report examines the latest issues, challenges, and developments in the rapidly evolving biosimilars market from the...
On behalf of Teva Pharmaceuticals, we are pleased to present the second edition of The Teva Biosimilars Trend Report. This report examines the latest issues, challenges, and developments in the rapidly evolving biosimilars market from the...
On behalf of Teva...
03/27/2025
First Report Managed Care

Interactive Features

Quiz
Monitoring AI Automation
11/25/2025
True or False: The transformation of traditional health care call centers into “smart access hubs” relies entirely on artificial intelligence (AI) to manage all patient interactions and scheduling.
True or False: The transformation of traditional health care call centers into “smart access hubs” relies entirely on artificial intelligence (AI) to manage all patient interactions and scheduling.
True or False: The...
11/25/2025
First Report Managed Care
Quiz
Mobile Health’s Expanding Role in Bridging Care Gaps Across the US
11/11/2025
11/11/2025
First Report Managed Care
Quiz
AI in Health Care: Potential and Pitfalls
11/11/2025
11/11/2025
First Report Managed Care
Quiz
Physician-Hospital Consolidation Spending Findings
10/29/2025
Hannah Musick
True or False: According to the GAO report, physician consolidation—particularly into hospital systems—has been linked to higher Medicare and commercial spending, with limited evidence that it improves care quality.
True or False: According to the GAO report, physician consolidation—particularly into hospital systems—has been linked to higher Medicare and commercial spending, with limited evidence that it improves care quality.
True or False: According to the...
10/29/2025
First Report Managed Care
Quiz
Member Engagement Options Under New Digital Marketplace
10/14/2025
True or False: UnitedHealthcare’s new UHC Store is a digital marketplace that allows members to purchase health insurance plans directly from the company.
True or False: UnitedHealthcare’s new UHC Store is a digital marketplace that allows members to purchase health insurance plans directly from the company.
True or False:...
10/14/2025
First Report Managed Care

Pipeline Projections

Pipe
Pipeline Projections
Emerging Migraine Treatments Challenge a Mature Market
11/20/2025
Roy Moore
Roy Moore of Clarivate’s market access team discussed the evolving migraine treatment landscape, highlighting the maturation of the acute and prophylactic markets, the emergence of new therapies such as triptan-COX-2 combinations, gepants,...
Roy Moore of Clarivate’s market access team discussed the evolving migraine treatment landscape, highlighting the maturation of the acute and prophylactic markets, the emergence of new therapies such as triptan-COX-2 combinations, gepants,...
Roy Moore of Clarivate’s market...
11/20/2025
First Report Managed Care
Pipeline Projections
Pipeline Projections
Redefining Asthma Management With Emerging Anti-Inflammatories
10/01/2025
Roy Moore
Roy Moore, a market access expert, discusses the evolving asthma drug pipeline, highlighting upcoming therapies—including Breztri, depemokimab, and masitinib—their potential to improve adherence and outcomes, payer considerations around cost...
Roy Moore, a market access expert, discusses the evolving asthma drug pipeline, highlighting upcoming therapies—including Breztri, depemokimab, and masitinib—their potential to improve adherence and outcomes, payer considerations around cost...
Roy Moore, a market access...
10/01/2025
First Report Managed Care
Pipeline Projections
The Shift in MS Care as Biologics and BTK Inhibitors Advance
07/25/2025
Roy Moore
In this edition of Pipeline Projections, Roy Moore breaks down the rapidly evolving landscape of multiple sclerosis treatments—highlighting the shift from injectables to orals, the rise of monoclonal antibodies, and the promise of innovative...
In this edition of Pipeline Projections, Roy Moore breaks down the rapidly evolving landscape of multiple sclerosis treatments—highlighting the shift from injectables to orals, the rise of monoclonal antibodies, and the promise of innovative...
In this edition of Pipeline...
07/25/2025
First Report Managed Care
Pipeline Projections
How Biosimilars Are Shaping RA Treatment and Reimbursement Strategies
04/29/2025
Roy Moore
In this episode of Pipeline Projections, Roy Moore—Senior Healthcare Research & Data Analyst at Clarivate—discusses the expanding biosimilar pipeline for autoimmune diseases. He highlights recent FDA approvals, formulary and pricing...
In this episode of Pipeline Projections, Roy Moore—Senior Healthcare Research & Data Analyst at Clarivate—discusses the expanding biosimilar pipeline for autoimmune diseases. He highlights recent FDA approvals, formulary and pricing...
In this episode of Pipeline...
04/29/2025
First Report Managed Care
Pipeline Projections
Examining Newly FDA-Approved Anticoagulants and Upcoming Drugs in the Approval Pipeline
02/12/2025
Roy Moore
In this episode of Pipeline Projections, Roy Moore—Senior Healthcare Research & Data Analyst at Clarivate and Editorial Board Member of First Report Managed Care—explores newly approved and existing anticoagulant therapies. He analyzes...
In this episode of Pipeline Projections, Roy Moore—Senior Healthcare Research & Data Analyst at Clarivate and Editorial Board Member of First Report Managed Care—explores newly approved and existing anticoagulant therapies. He analyzes...
In this episode of Pipeline...
02/12/2025
First Report Managed Care

Behind the Bill

Behind the Bill
HHS Hits Reset on 340B Rebate Model After Court Setbacks
02/11/2026
Juliet Gallagher
The US Department of Health and Human Services (HHS) has formally scrapped its 340B Rebate Model Pilot Program following a series of court rulings that blocked its implementation—signaling a significant pause in one of the most closely...
The US Department of Health and Human Services (HHS) has formally scrapped its 340B Rebate Model Pilot Program following a series of court rulings that blocked its implementation—signaling a significant pause in one of the most closely...
The US Department of Health and...
02/11/2026
First Report Managed Care
Behind the Bill
Funding Package Extends Medicare Telehealth, Enacts PBM Reforms, and Updates Hospital Oversight
02/05/2026
Juliet Gallagher
On February 3, 2026, President Donald Trump signed a broad government funding package that includes multi-year extensions for Medicare teleath and hospital-at-home programs, new oversight requirements for pharmacy benefit managers (PBMs), and...
On February 3, 2026, President Donald Trump signed a broad government funding package that includes multi-year extensions for Medicare teleath and hospital-at-home programs, new oversight requirements for pharmacy benefit managers (PBMs), and...
On February 3, 2026, President...
02/05/2026
First Report Managed Care
Behind the Bill
The Senate’s $3 Trillion Deal. Tax Relief Now, Medicaid Coverage Loss Later?
07/02/2025
Katie Hayes, MJ
The Senate has done it. After weeks of behind-the-scenes wrangling and last-minute amendments, lawmakers have passed a sprawling tax-and-spending megabill that makes good on a long-standing Republican goal: making the 2017 Trump tax cuts...
The Senate has done it. After weeks of behind-the-scenes wrangling and last-minute amendments, lawmakers have passed a sprawling tax-and-spending megabill that makes good on a long-standing Republican goal: making the 2017 Trump tax cuts...
The Senate has done it. After...
07/02/2025
First Report Managed Care
Behind the Bill
When a Cap Isn’t Just a Cap: How a Provider Tax Proposal Could Reshape Medicaid Financing
06/25/2025
Katie Hayes, MJ
In Washington, the most consequential policies are often buried in the fine print. One such detail in the Senate Finance Committee’s latest tax and spending proposal would gradually cap provider taxes—a core funding tool states use to pull in...
In Washington, the most consequential policies are often buried in the fine print. One such detail in the Senate Finance Committee’s latest tax and spending proposal would gradually cap provider taxes—a core funding tool states use to pull in...
In Washington, the most...
06/25/2025
First Report Managed Care
Behind the Bill
Rewriting the Safety Net? Inside the Senate’s Changes to Medicaid and the ACA
06/18/2025
Katie Hayes, MJ
Over the past few weeks, I’ve been following the progress of the One Big Beautiful Bill Act (OBBBA), which started in the House with sweeping tax reforms and some eye-catching health care proposals. Now, the Senate has released its (highly...
Over the past few weeks, I’ve been following the progress of the One Big Beautiful Bill Act (OBBBA), which started in the House with sweeping tax reforms and some eye-catching health care proposals. Now, the Senate has released its (highly...
Over the past few weeks, I’ve...
06/18/2025
First Report Managed Care
Behind the Bill
How States Might Respond to the One Big Beautiful Bill Act
06/11/2025
Katie Hayes, MJ
With the One Big Beautiful Bill Act (OBBBA) still in the hands of the Senate, much of the national conversation has centered on what this legislation would do to federal coverage programs. But regardless of how the federal process unfolds,...
With the One Big Beautiful Bill Act (OBBBA) still in the hands of the Senate, much of the national conversation has centered on what this legislation would do to federal coverage programs. But regardless of how the federal process unfolds,...
With the One Big Beautiful Bill...
06/11/2025
First Report Managed Care
Behind the Bill
Is the Affordable Care Act on the Chopping Block? What the One Big Beautiful Bill Act Tells Us.
06/04/2025
Katie Hayes, MJ
It’s been weeks of headline-grabbing debate over Medicaid work requirements, and the “One Big Beautiful Bill Act” remains in the Senate as they deliberate over several health care provisions. While the Medicaid provisions sparked most of the...
It’s been weeks of headline-grabbing debate over Medicaid work requirements, and the “One Big Beautiful Bill Act” remains in the Senate as they deliberate over several health care provisions. While the Medicaid provisions sparked most of the...
It’s been weeks of...
06/04/2025
First Report Managed Care
Behind the Bill
From House to Senate: The Journey of Cutting Medicaid
05/28/2025
Katie Hayes, MJ
Last week, the House of Representatives narrowly passed the One Big Beautiful Bill Act (HR 1, 119th Congress) by a single vote, sending the sweeping tax and spending reconciliation package, backed by President Trump, to the Senate. With its...
Last week, the House of Representatives narrowly passed the One Big Beautiful Bill Act (HR 1, 119th Congress) by a single vote, sending the sweeping tax and spending reconciliation package, backed by President Trump, to the Senate. With its...
Last week, the House of...
05/28/2025
First Report Managed Care
Behind the Bill
Eligibility, Paperwork, and Penalties: The Not-So-Hidden Costs of Medicaid ‘Reform’
05/21/2025
Katie Hayes, MJ
It’s been another eventful week in health policy—a phrase that’s quickly becoming routine. This time, House Republicans advanced a sweeping budget reconciliation bill, designed to implement elements of the March budget resolution, with a...
It’s been another eventful week in health policy—a phrase that’s quickly becoming routine. This time, House Republicans advanced a sweeping budget reconciliation bill, designed to implement elements of the March budget resolution, with a...
It’s been another eventful week...
05/21/2025
First Report Managed Care
Behind the Bill
A Busy Week in Drug Pricing Policy: Aligning US Drug Prices With Global Standards?
05/14/2025
Katie Hayes, MJ
It’s been a busy few days for drug pricing policy. While I’d love to dig into the details of both President Trump’s latest executive order and the newest Republican bill that would cut Medicaid spending, we don’t have the time—and this isn’t...
It’s been a busy few days for drug pricing policy. While I’d love to dig into the details of both President Trump’s latest executive order and the newest Republican bill that would cut Medicaid spending, we don’t have the time—and this isn’t...
It’s been a busy few days for...
05/14/2025
First Report Managed Care

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use